- Home
- BLUE vs INKT Comparison
BLUE vs INKT Comparison
Compare BLUE & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLUE
- INKT
- Stock Information
- Founded
- BLUE 1992
- INKT 2017
- Country
- BLUE United States
- INKT United States
- Employees
- BLUE N/A
- INKT N/A
- Industry
- BLUE Biotechnology: Biological Products (No Diagnostic Substances)
- INKT Medicinal Chemicals and Botanical Products
- Sector
- BLUE Health Care
- INKT Health Care
- Exchange
- BLUE Nasdaq
- INKT Nasdaq
- Market Cap
- BLUE 36.9M
- INKT 33.6M
- IPO Year
- BLUE 2013
- INKT 2021
- Fundamental
- Price
- BLUE $5.25
- INKT $8.79
- Analyst Decision
- BLUE Hold
- INKT Strong Buy
- Analyst Count
- BLUE 7
- INKT 2
- Target Price
- BLUE $44.60
- INKT $37.50
- AVG Volume (30 Days)
- BLUE 512.7K
- INKT 9.1K
- Earning Date
- BLUE 03-27-2025
- INKT 03-18-2025
- Dividend Yield
- BLUE N/A
- INKT N/A
- EPS Growth
- BLUE N/A
- INKT N/A
- EPS
- BLUE N/A
- INKT N/A
- Revenue
- BLUE $83,807,000.00
- INKT N/A
- Revenue This Year
- BLUE $218.58
- INKT N/A
- Revenue Next Year
- BLUE N/A
- INKT N/A
- P/E Ratio
- BLUE N/A
- INKT N/A
- Revenue Growth
- BLUE 184.12
- INKT N/A
- 52 Week Low
- BLUE $3.56
- INKT $4.56
- 52 Week High
- BLUE $28.60
- INKT $19.00
- Technical
- Relative Strength Index (RSI)
- BLUE 63.49
- INKT 50.92
- Support Level
- BLUE $3.65
- INKT $8.60
- Resistance Level
- BLUE $5.42
- INKT $9.23
- Average True Range (ATR)
- BLUE 0.31
- INKT 0.85
- MACD
- BLUE 0.25
- INKT 0.08
- Stochastic Oscillator
- BLUE 90.40
- INKT 52.83
About BLUE bluebird bio Inc.
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.